(3R,4S)-3-fluoro-N,1-dimethylpiperidin-4-amine | 845256-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,4S)-3-fluoro-N,1-dimethylpiperidin-4-amine
• CAS: 845256-63-5
• 化学式: C₇H₁₅FN₂
• 分子量: 146.208
• InChiKey: HYTUIXWVBMRTAN-RQJHMYQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R,4S)-3-fluoro-N,1-dimethylpiperidin-4-amine 、 3-((2-chlorothieno-[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile 以 乙酸乙酯 为溶剂， 反应 1.5h， 生成 3-((2-((3R,4S)-3-fluoro-4-(methylamino)piperidin-1-yl)thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile
  参考文献：
  名称：

  Novel Thienopyrimidine Inhibitors of Leishmania N-Myristoyltransferase with On-Target Activity in Intracellular Amastigotes

  摘要：

  The leishmaniases, caused by Leishmania species of protozoan parasites, are neglected tropical diseases with millions of cases worldwide. Current therapeutic approaches are limited by toxicity, resistance, and cost. N-Myristoyltransferase (NMT), an enzyme ubiquitous and essential in all eukaryotes, has been validated via genetic and pharmacological methods as a promising anti- leishmanial target. Here we describe a comprehensive structure-activity relationship (SAR) study of a thienopyrimidine series previously identified in a high-throughput screen against Leishmania NMT, across 68 compounds in enzyme- and cell-based assay formats. Using a chemical tagging target engagement biomarker assay, we identify the first inhibitor in this series with on-target NMT activity in leishmania parasites. Furthermore, crystal structure analyses of 12 derivatives in complex with Leishmania major NMT revealed key factors important for future structure-guided optimization delivering IMP-105 (43), a compound with modest activity against Leishmania donovani intracellular amastigotes and excellent selectivity (>660-fold) for Leishmania NMT over human NMTs.

  DOI：

  10.1021/acs.jmedchem.0c00570
• 作为产物：
  描述：

  benzyl (3R,4S)-4-[(tert-butoxycarbonyl)(methyl)amino]-3-fluoropiperidine-1-carboxylate 在 palladium 10% on activated carbon 盐酸 、 1,4-环己二烯 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 7.0h， 生成 (3R,4S)-3-fluoro-N,1-dimethylpiperidin-4-amine
  参考文献：
  名称：

  WO2006/101780

  摘要：

  公开号：

文献信息

• Mitotic kinesin inhibitors
  申请人：Coleman J. Paul

  公开号：US20050038074A1

  公开（公告）日：2005-02-17

  The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及对治疗细胞增殖性疾病、治疗与KSP动力蛋白活性相关的疾病以及抑制KSP动力蛋白的二氢吡咯化合物。该发明还涉及包含这些化合物的组合物，以及利用它们治疗哺乳动物癌症的方法。
• BENZOPYRANOPYRAZOLES
  申请人：Vennemann Matthias

  公开号：US20100104659A1

  公开（公告）日：2010-04-29

  Compounds of a certain formula I, in which Ra, Rb and Rc have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

  某个化学式I的化合物，其中Ra、Rb和Rc具有说明中指定的含义，是具有抗增殖和/或诱导细胞凋亡活性的有效化合物。
• [EN] MITOTIC KINESIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KINESINE MITOTIQUE
  申请人：MERCK & CO INC

  公开号：WO2005019206A1

  公开（公告）日：2005-03-03

  The present invention relates to dihydropyrrole compounds of Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及式(I)的二氢吡咯化合物，其对治疗细胞增殖性疾病、治疗与KSP动力蛋白活性相关的疾病以及抑制KSP动力蛋白具有用途。本发明还涉及包含这些化合物的组合物以及使用它们治疗哺乳动物癌症的方法。
• Process for the Preparation of 2,2-Disubstituted Pyrroles
  申请人：Javadi Gary

  公开号：US20070225499A1

  公开（公告）日：2007-09-27

  The present invention relates to the stereoselective preparation of 2,2-disubstituted-4-carbonatepyrroles from readily available chiral starting materials. Such pyrroles are useful as intermediates in the preparation of 2,2,4-trisubstituted 2,5-dihydropyrroles, that are inhibitors of mitotic kinesins and are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The product of the process of the invention may be illustrated by the Formula (I).

  本发明涉及从易得手性起始材料中立体选择性地制备2,2-二取代-4-碳酸酯吡咯的方法。这样的吡咯在制备2,2,4-三取代-2,5-二氢吡咯的中间体时非常有用，该中间体是有丝分裂动力蛋白酶抑制剂，可用于治疗细胞增殖性疾病，治疗与KSP动力蛋白酶活性相关的疾病，并抑制KSP动力蛋白酶。本发明的产物可以用式(I)表示。
• Mitotic Kinesin Inhibitors
  申请人：Coleman Paul J.

  公开号：US20080207693A1

  公开（公告）日：2008-08-28

  The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及二氢吡唑化合物，对于治疗细胞增殖性疾病，治疗与KSP动力蛋白活性相关的疾病，以及抑制KSP动力蛋白具有用处。该发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。